The preclinical inhibitor ML323 selectively targets USP1–UAF1, increases PCNA-Ub and FANCD2-Ub, amplifies replication stress, promotes apoptosis, and sensitizes tumor cells to cisplatin, suggesting a route to overcome platinum resistance [82–84]. This evidence concerns the gene PCNA and neoplasm.